Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma

Dina Bassiouny, Nadia Ismiil, Valerie Dubé, Guangming Han, Matthew Cesari, Fang I. Lu, Elzbieta Slodkowska, Carlos Parra-Herran, Hak Fai Chiu, Magda Naeim, Nim Li, Mahmoud A Khalifa, Sharon Nofech-Mozes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.

Original languageEnglish (US)
Pages (from-to)306-317
Number of pages12
JournalInternational Journal of Surgical Pathology
Volume26
Issue number4
DOIs
StatePublished - Jun 1 2018
Externally publishedYes

Fingerprint

Mucinous Adenocarcinoma
Recurrence
Therapeutics
Neoplasms
Proteins

Keywords

  • HER2
  • HNF1b
  • PAX8
  • SATB2
  • immunohistochemistry
  • mucinous
  • napsin A
  • ovarian cancer

PubMed: MeSH publication types

  • Journal Article

Cite this

Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma. / Bassiouny, Dina; Ismiil, Nadia; Dubé, Valerie; Han, Guangming; Cesari, Matthew; Lu, Fang I.; Slodkowska, Elzbieta; Parra-Herran, Carlos; Chiu, Hak Fai; Naeim, Magda; Li, Nim; Khalifa, Mahmoud A; Nofech-Mozes, Sharon.

In: International Journal of Surgical Pathology, Vol. 26, No. 4, 01.06.2018, p. 306-317.

Research output: Contribution to journalArticle

Bassiouny, D, Ismiil, N, Dubé, V, Han, G, Cesari, M, Lu, FI, Slodkowska, E, Parra-Herran, C, Chiu, HF, Naeim, M, Li, N, Khalifa, MA & Nofech-Mozes, S 2018, 'Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma' International Journal of Surgical Pathology, vol. 26, no. 4, pp. 306-317. https://doi.org/10.1177/1066896917752861
Bassiouny, Dina ; Ismiil, Nadia ; Dubé, Valerie ; Han, Guangming ; Cesari, Matthew ; Lu, Fang I. ; Slodkowska, Elzbieta ; Parra-Herran, Carlos ; Chiu, Hak Fai ; Naeim, Magda ; Li, Nim ; Khalifa, Mahmoud A ; Nofech-Mozes, Sharon. / Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma. In: International Journal of Surgical Pathology. 2018 ; Vol. 26, No. 4. pp. 306-317.
@article{e8621afbdde8411087c3228adb3df69b,
title = "Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma",
abstract = "The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3{\%}), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7{\%}), 35 (97.2{\%}), and 0 (0{\%}), respectively. MMR proteins and ARID1A were retained in 100{\%}; PTEN was lost in 4 (11.1{\%}). P53 was aberrant in 10 (27.8{\%}); none overexpressed p16. HER2 was positive in 6/35 (17.1{\%}). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.",
keywords = "HER2, HNF1b, PAX8, SATB2, immunohistochemistry, mucinous, napsin A, ovarian cancer",
author = "Dina Bassiouny and Nadia Ismiil and Valerie Dub{\'e} and Guangming Han and Matthew Cesari and Lu, {Fang I.} and Elzbieta Slodkowska and Carlos Parra-Herran and Chiu, {Hak Fai} and Magda Naeim and Nim Li and Khalifa, {Mahmoud A} and Sharon Nofech-Mozes",
year = "2018",
month = "6",
day = "1",
doi = "10.1177/1066896917752861",
language = "English (US)",
volume = "26",
pages = "306--317",
journal = "International Journal of Surgical Pathology",
issn = "1066-8969",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma

AU - Bassiouny, Dina

AU - Ismiil, Nadia

AU - Dubé, Valerie

AU - Han, Guangming

AU - Cesari, Matthew

AU - Lu, Fang I.

AU - Slodkowska, Elzbieta

AU - Parra-Herran, Carlos

AU - Chiu, Hak Fai

AU - Naeim, Magda

AU - Li, Nim

AU - Khalifa, Mahmoud A

AU - Nofech-Mozes, Sharon

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.

AB - The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.

KW - HER2

KW - HNF1b

KW - PAX8

KW - SATB2

KW - immunohistochemistry

KW - mucinous

KW - napsin A

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85041922271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041922271&partnerID=8YFLogxK

U2 - 10.1177/1066896917752861

DO - 10.1177/1066896917752861

M3 - Article

VL - 26

SP - 306

EP - 317

JO - International Journal of Surgical Pathology

JF - International Journal of Surgical Pathology

SN - 1066-8969

IS - 4

ER -